Jul 2026· Advancement of science· 0 citations· 58 references
Medicine
TL;DR
The structural basis by which specific mutations enhance cross‐variant recognition of SARS‐CoV‐2 is defined, highlighting the underappreciated breadth encoded within the naïve B‐cell repertoire and providing a conceptual framework for engineering and eliciting antibody responses resilient to future antigenic drift.
Abstract
ABSTRACT Rapid antigenic drift of the SARS‐CoV‐2 receptor‐binding domain (RBD) underlies immune escape and continues to challenge the durability of antibody‐mediated protection. Among the major classes of RBD‐directed antibodies, germline‐encoded IGHV3‐53 responses are highly potent against early SARS‐CoV‐2 variants but are generally compromised by Omicron‐associated mutations. Here, we identify an intrinsically cross‐reactive IGHV3‐53 germline antibody that recognizes multiple pre‐Omicron variants, including SARS‐CoV‐2 wild‐type, Alpha, and Delta. Notably, we demonstrate that targeted somatic evolution can further expand this breadth to overcome the immune escape of different Omicron variants. Guided by integrated structural and sequence analyses, we introduce four somatic mutations (G26E, T28I, S53P, and Y58F) into the germline antibody, resulting in markedly enhanced binding and neutralization of Omicron BA.1, and BA.4/5. High‐resolution crystal structures reveal that these mutations re‐establish interactions disrupted by substitutions in the Omicron RBD and improve binding at a remodeled epitope interface. Collectively, our findings define the structural basis by which specific mutations enhance cross‐variant recognition of SARS‐CoV‐2. This work highlights the underappreciated breadth encoded within the naïve B‐cell repertoire and provides a conceptual framework for engineering and eliciting antibody responses resilient to future antigenic drift.
This work assessed whether non‐broadly neutralizing IGHV3‐53/3‐66 antibodies could mature into broadly neutralizing antibodies and found some acquire broad neutralizing activity through accumulation of somatic hypermutations.
Takeo Kuwata, K. Okazaki, Hiroshi Morioka et al.· Immunity, Inflammation and D...· 0 citations
Two human-derived monoclonal antibodies are characterized that recognize conserved epitopes on the SARS-CoV-2 RBD and retain activity across antigenically distinct variants, and conserved, mutationally constrained epitopes may serve as targets for vaccines designed to elicit antibody responses resilient to ongoing SARS...
M. Abernathy, William B. Foreman, Jasmyn A. Lopez et al.· bioRxiv· 0 citations
Findings demonstrate that both the nature and number of antigenic exposures can shape the potency and breadth of SARS‐CoV‐2 neutralizing responses, emphasizing the need for continued variant monitoring and periodic vaccine reformulation to maintain population‐level protection.
Greta Vizgirda, Alexander P. Underwood, Ulrik Fahnøe et al.· Journal of Medical Virology· 0 citations
RHS is established as a generalizable strategy for overcoming viral immune evasion and advancing next‐generation vaccine design, and is readily adaptable to antigens from SARS‐CoV and MERS‐CoV, underscoring its versatility for pan‐coronavirus vaccine development.
Xi-Kui Sun, Junhao Fan, Xiaolu Xie et al.· Advancement of science· 0 citations
Mechanistic studies reveal that NTD-5 and NTD-9 antibodies neutralize by inducing S1 shedding, thereby extending this mechanism to selected NTD-directed antibodies and providing a structural and mechanistic framework for rational vaccine and antibody design resilient to antigenic drift.
Jian-Jie Zhou, Wen-Yu Li, Xiaoyu Wang et al.· Proceedings of the National...· 0 citations
The findings suggest that SARS-CoV-2 antigenic evolution follows the pattern of multiple pathways within a constrained space, providing new insights into the adaptive mechanisms of Omicron-derived variants under hybrid immune pressure.
Cheng-Wei Shao, Jian-Guang Fu, Fei Deng et al.· Microorganisms· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.